• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling.
Classification Namepermanent defibrillator electrodes
Generic Namepermanent defibrillator electrodes
8200 coral sea street ne
ms mv s11
mounds view, MN 55112
PMA NumberP920015
Date Received04/01/1992
Decision Date12/09/1993
Product Code
NVY[ Registered Establishments with NVY ]
Docket Number 94M-0063
Notice Date 04/19/1994
Advisory Committee Cardiovascular
Expedited Review Granted? Yes
Combination Product Yes
Recalls CDRH Recalls
Approval Order Statement 
Approval for the Medtronic Transvene® Lead System. This device is intended for single long-term use and each lead is designed to be used only with a compatible Medtronic implantable tachyarrhytmia control device along with at least one other Medtronic defibrillation lead. The lead system has application where implantable e tachyarrhythmia cardioversion or defibrillation systems are indicated. Current medical research indicates that such patients should: (1) have survived at least one episode of a cardiac arrest presumably due to a ventricular tachyarrhythmia as evidenced by resuscitation using a transthoracic defibrillator. The ventricular tachyarrhythmia should not be caused by an acute myocardial infarction; or (2) in the absence of a of a prior cardiac arrest, have poorly tolerated sustained VT and/or VF, which occurs spontaneously, or can be induced, despite the best antiarrhythmic drug therapy.The natural history of patients with hemodynamically stable sustained VT is not well defined. While this patient population was included in the Transvene® Lead clinical study, no conclusions were drawn from the data obtained on this specific patient group.Prior to Transvene® implant, it is strongly recommended that patients undergo a complete cardiac evaluation, which should include extensive electrophysiologic testing. Also, extensive electrophysiologic evaluation and testing of the safety and efficacy of the proposed pacing, cardioversion, or defibrillation therapies are recommended during and after the implantation of the Transvene® System.
Post-Approval StudyShow Report Schedule and Study Progress
Supplements: S001 S002 S003 S004 S005 S006 S007 S008 S009 
S010 S011 S012 S013 S014 S015 S016 S017 S020 
S021 S022 S023 S024 S025 S027 S028 S029 S030 
S031 S032 S035 S036 S037 S038 S039 S040 S041 
S042 S043 S044 S045 S046 S047 S049 S050 S051 
S052 S053 S054 S055 S056 S057 S058 S059 S061 
S062 S063 S064 S065 S067 S068 S069 S070 S071 
S072 S073 S074 S075 S076 S077 S078 S079 S080 
S081 S082 S083 S084 S085 S086 S087 S088 S089 
S090 S091 S092 S093 S094 S095 S096 S097 S098 
S099 S100 S101 S102 S103 S104 S105 S106 S107 
S108 S109 S111 S113 S114 S116 S117 S118 S119 
S120 S121 S122 S123 S124 S125 S126 S127 S128 
S129 S131 S132 S133 S134 S135 S136 S137 S138 
S139 S140 S141 S142 S143 S144 S145 S146 S147 
S148 S149 S150 S151 S152 S153 S155 S156 S157 
S158 S159 S160 S161 S162 S163 S164 S165 S166 
S167 S168 S169 S170 S171 S172 S173 S174 S175 
S176 S177 S178 S179 S180 S181 S182 S183 S184 
S185 S186 S187 S188 S189 S190 S191 S192 S193 
S194 S195 S196 S197 S198 S199 S200 S201 S202 
S203 S204 S205 S206 S207 S208 S209 S210 S211 
S212 S213 S214 S215 S216 S217 S218 S219 S220 
S221 S222 S223 S224 S225 S226 S227 S228 S229 
S230 S231 S232 S233 S235 S236